EUVIMEDEUVIMED entdecken
Crossref

99m Tc ‐ HP ‐Ark2 SPECT / CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition

Xiuting Lin iD, Zhenying Chen, Junyu Lin, Chao Huang, Jiyun Shi, Fan Wang, Weibing Miao

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xiuting Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab is a first‐line treatment for human epidermal growth receptor 2 (HER2)‐positive breast cancer, but resistance severely limits its efficacy, with underlying mechanisms involving HER2 expression still requiring further elucidation. This study aimed to investigate the dynamic changes in HER2 expression during the development and reversal of trastuzumab resistance, and to evaluate the utility of a novel HER2‐targeting molecular probe, 99m Tc‐HP‐Ark2, for non‐invasive, real‐time monitoring of HER2 status and treatment response. Trastuzumab‐resistant SK‐BR‐3R cells, established through chronic exposure of parental SK‐BR‐3 cells to increasing concentrations of trastuzumab, exhibited stable resistance (resistance index = 13.79), accompanied by significant upregulation of HER2 and phosphorylated PI3K (p‐PI3K) expression. Treatment with the PI3K inhibitor LY294002 effectively inhibited p‐PI3K activation and substantially reduced HER2 expression. Notably, the combination of LY294002 with trastuzumab led to a more pronounced downregulation of HER2 and restored trastuzumab sensitivity in SK‐BR‐3R cells. In vivo SPECT/CT imaging consistently showed significantly higher 99m Tc‐HP‐Ark2 uptake in SK‐BR‐3R tumors compared to SK‐BR‐3 tumors, which markedly decreased upon treatment with LY294002 alone or in combination with trastuzumab. Immunohistochemistry (IHC) analysis confirmed a strong positive correlation between changes in HER2 expression and tumor radioactive uptake trends. This study highlights the pivotal role of HER2 as a dynamic biomarker in trastuzumab resistance and supports the integration of molecular imaging into clinical decision‐making for personalized therapeutic adjustments in HER2‐positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmBreast NeoplasmsPhosphoinositide-3 Kinase InhibitorsSingle Photon Emission Computed Tomography Computed TomographyHumansFemaleCell Line, TumorMiceAnimalsPhosphatidylinositol 3-KinasesMorpholinesXenograft Model Antitumor AssaysChromonesMice, Nude

Stichwörter der Autor:innen

99mTc‐HP‐Ark2HER2PI3K inhibitorresistancetrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsMorpholinesChromones2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Nuclear Medicine, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Thyroid and Breast Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Medical Isotopes Research Center and Department of Radiation Medicine, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University, Beijing, China.
  • Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.

ORCID-Profile: Xiuting Lin

Förderung

  • Joint Funds for the Innovation of Science and Technology, Fujian Province
  • National Natural Science Foundation of China

Zitieren

APA

Lin, X., Chen, Z., Lin, J., Huang, C., Shi, J., Wang, F., & Miao, W. (2026). 99m Tc ‐ HP ‐Ark2 SPECT / CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition. International Journal of Cancer. https://doi.org/10.1002/ijc.70235

Vancouver

Lin X, Chen Z, Lin J, Huang C, Shi J, Wang F, et al. 99m Tc ‐ HP ‐Ark2 SPECT / CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition. International Journal of Cancer. 2026. doi:10.1002/ijc.70235

BibTeX
@article{Lin2026,
  author = {Lin, Xiuting and Chen, Zhenying and Lin, Junyu and Huang, Chao and Shi, Jiyun and Wang, Fan and Miao, Weibing},
  title = {99m Tc ‐ HP ‐Ark2 SPECT / CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70235}
}
Kostenlos starten →